This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Eidem TM , Lounsbury N , Emery JF , Bulger J , Smith A , Abou-Gharbia M , Childers W , Dunman PM
Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing
Antimicrob Agents Chemother. 2015 Apr;59(4) :2016-28
PMID: 25605356 PMCID: PMC4356807
AbstractNew agents are urgently needed for the therapeutic treatment of Staphylococcus aureus infections. In that regard, S. aureus RNase RnpA may represent a promising novel dual-function antimicrobial target that participates in two essential cellular processes, RNA degradation and tRNA maturation. Accordingly, we previously used a high-throughput screen to identify small-molecule inhibitors of the RNA-degrading activity of the enzyme and showed that the RnpA inhibitor RNPA1000 is an attractive antimicrobial development candidate. In this study, we used a series of in vitro and cellular assays to characterize a second RnpA inhibitor, RNPA2000, which was identified in our initial screening campaign and is structurally distinct from RNPA1000. In doing so, it was found that S. aureus RnpA does indeed participate in 5'-precursor tRNA processing, as was previously hypothesized. Further, we show that RNPA2000 is a bactericidal agent that inhibits both RnpA-associated RNA degradation and tRNA maturation activities both in vitro and within S. aureus. The compound appears to display specificity for RnpA, as it did not significantly affect the in vitro activities of unrelated bacterial or eukaryotic ribonucleases and did not display measurable human cytotoxicity. Finally, we show that RNPA2000 exhibits antimicrobial activity and inhibits tRNA processing in efflux-deficient Gram-negative pathogens. Taken together, these data support the targeting of RnpA for antimicrobial development purposes, establish that small-molecule inhibitors of both of the functions of the enzyme can be identified, and lend evidence that RnpA inhibitors may have broad-spectrum antimicrobial activities.
NotesEidem, Tess M Lounsbury, Nicole Emery, John F Bulger, Jeffrey Smith, Andrew Abou-Gharbia, Magid Childers, Wayne Dunman, Paul M AI073780/AI/NIAID NIH HHS/United States AI103507/AI/NIAID NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28. doi: 10.1128/AAC.04352-14. Epub 2015 Jan 20.